Skip to main content

View full-text article in PMC

. 2023 Jun 28;8(8):755–764. doi: 10.1001/jamacardio.2023.1729

Table 2. Clinical Outcomes in the Study Population.

Outcome	Participants, No. (%)			Hazard ratio (95% CI)	P value
Outcome	Total (N = 704)	Low coronary atherosclerotic plaque activity (n = 283)^a	High coronary atherosclerotic plaque activity (n = 421)^b	Hazard ratio (95% CI)	P value
Primary end point	141 (20.0)	51 (18.0)	90 (21.4)	1.25 (0.89-1.76)	.20
All-cause death	39 (5.5)	9 (3.2)	30 (7.1)	2.43 (1.15-5.12)	.02
Components of the primary end point
Cardiac death	12 (1.7)	2 (0.7)	10 (2.4)	3.51 (0.77-16.04)	.10
Nonfatal myocardial infarction	54 (7.7)	17 (6.0)	37 (8.8)	1.61 (0.91-2.86)	.10
Unscheduled coronary revascularization	87 (12.4)	36 (12.7)	51 (12.1)	0.98 (0.64-1.49)	.91
Cardiac death or nonfatal myocardial infarction	66 (9.4)	19 (6.7)	47 (11.2)	1.82 (1.07-3.10)	.03

Abbreviation: CMA, coronary microcalcification activity.

^{^a}

Low coronary atherosclerotic plaque activity was defined as a CMA of 0.

^{^b}

High coronary atherosclerotic plaque activity was defined as a CMA greater than 0.